Want to see IN:APLLTD full AI Analyst Report?
APLLTD Stock Chart & Stats
₹796.50
₹16.85(2.11%)
At close: 4:00 PM EDT
₹796.50
₹16.85(2.11%)
Day’s Range― - ―
52-Week Range₹635.30 - ₹1,004.95
Previous CloseN/A
Volume50.27K
Average Volume (3M)9.71K
Market Cap
₹156.67B
Enterprise Value₹142.31K
Total Cash (Recent Filing)₹2.03B
Total Debt (Recent Filing)₹14.30B
Price to Earnings (P/E)23.2
Beta1.01
Next Earnings
Nov 10, 2026EPS Estimate
9.1Next Dividend Ex-DateN/A
Dividend Yield1.5%
Share Statistics
EPS (TTM)34.32
Shares Outstanding196,563,130
10 Day Avg. Volume3,953
30 Day Avg. Volume9,706
Financial Highlights & Ratios
PEG Ratio1.23
Price to Book (P/B)2.30
Price to Sales (P/S)1.77
P/FCF Ratio50.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)37.58
Revenue Forecast (FY)₹82.00B
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthConsistent multi-year revenue growth reflects durable demand across branded generics and API businesses. That steady top-line expansion supports scale benefits, continued commercial investment and predictable capacity utilization, underpinning medium-term earnings resilience and market presence.
Conservative Balance SheetA low debt-to-equity ratio and expanding shareholders' equity provide financial flexibility to fund launches, capex or opportunistic M&A without stressing cash flows. Conservative leverage lowers refinancing risk and improves the company's ability to absorb cyclical setbacks over the medium term.
Rebound To Positive Free Cash FlowReturn to positive operating and free cash flow in 2026 demonstrates the firm's capacity to convert earnings into cash when operational execution stabilizes. Sustainable FCF enables reinvestment in manufacturing and R&D, debt reduction and supports shareholder distributions over time.
Bears Say
Volatile Cash GenerationLarge year-to-year swings in operating and free cash flow point to working-capital sensitivity or execution variability. Persistent volatility can restrict capital allocation, force external financing in weak years, and increase uncertainty around sustaining investments and returns.
Margin Compression Vs PeakNet margin down to ~9% in 2026 from materially higher levels earlier indicates reduced earnings power. Compression limits internal funding for growth and makes profitability more vulnerable to pricing or input-cost shocks, weakening long-term cash generation potential.
Competitive Pressure In GenericsHeavy reliance on generics and product-by-product launches—especially in the US—exposes revenues to structural pricing decline and intense competitor entry. Success hinges on continuous approvals and launches, making medium-term revenue visibility and margin stability uncertain.
Alembic Pharmaceuticals Limited News
APLLTD FAQ
What was Alembic Pharmaceuticals Limited’s price range in the past 12 months?
Alembic Pharmaceuticals Limited lowest stock price was ₹635.30 and its highest was ₹1004.95 in the past 12 months.
What is Alembic Pharmaceuticals Limited’s market cap?
Alembic Pharmaceuticals Limited’s market cap is ₹156.67B.
When is Alembic Pharmaceuticals Limited’s upcoming earnings report date?
Alembic Pharmaceuticals Limited’s upcoming earnings report date is Nov 10, 2026 which is in 97 days.
How were Alembic Pharmaceuticals Limited’s earnings last quarter?
Alembic Pharmaceuticals Limited released its earnings results on Aug 04, 2026. The company reported ₹8.8 earnings per share for the quarter, beating the consensus estimate of ₹7.788 by ₹1.012.
Is Alembic Pharmaceuticals Limited overvalued?
According to Wall Street analysts Alembic Pharmaceuticals Limited’s price is currently Overvalued.
Does Alembic Pharmaceuticals Limited pay dividends?
Alembic Pharmaceuticals Limited pays a Annually dividend of ₹12 which represents an annual dividend yield of 1.5%. See more information on Alembic Pharmaceuticals Limited dividends here
What is Alembic Pharmaceuticals Limited’s EPS estimate?
Alembic Pharmaceuticals Limited’s EPS estimate is 9.1.
How many shares outstanding does Alembic Pharmaceuticals Limited have?
Alembic Pharmaceuticals Limited has 196,563,130 shares outstanding.
What happened to Alembic Pharmaceuticals Limited’s price movement after its last earnings report?
Alembic Pharmaceuticals Limited reported an EPS of ₹8.8 in its last earnings report, beating expectations of ₹7.788. Following the earnings report the stock price went up 0.434%.
Which hedge fund is a major shareholder of Alembic Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:APLLTD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited is a pharmaceutical firm that develops, manufactures, and markets medicinal products both domestically in India and across international markets. Its offerings encompass active pharmaceutical ingredients (APIs) and a wide array of formulations. The company provides both proprietary (branded) and generic medications, addressing numerous therapeutic needs such as cardiovascular health, women's health, gastrointestinal issues, eye and skin conditions, kidney/urinary tract disorders, orthopedic ailments, anti-infective treatments, remedies for cold and cough, and anti-diabetic management. Furthermore, the company engages in the export of its diverse product portfolio. Founded in 1907, Alembic Pharmaceuticals Limited maintains its main office in Vadodara, India.
Technical Analysis
Glenmark Life Sciences Limited
―
Granules India Limited
―
Jubilant Pharmova Limited
―
NATCO Pharma Limited
―
Piramal Pharma Limited
―